How does AEQ's PS Ratio compare to its peers?

AEQ is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (4.2x).

How does AEQ's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

AEQ is good value based on its Price-To-Sales Ratio (1.6x) compared to the European Pharmaceuticals industry average (3.1x).

What is AEQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate AEQ's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of AEQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate AEQ's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Aequus Pharmaceuticals (DB:AEQ) - Stock Price, News & Analysis

AEQ Stock Overview

A specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. More details

AEQ fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Earnings have declined by 7.4% per year over past 5 years

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (CA$413K)

Does not have a meaningful market cap (€663K)

+ 2 more risks

Aequus Pharmaceuticals Inc. Competitors

Valeo Pharma

DB:VP2

€493.4k

Biofrontera

XTRA:B8FK

€16.4m

Epigenomics

DB:ECX

€1.2m

SynBiotic

DUSE:SBX

€27.9m

Price History & Performance

Summary of all time highs, changes and price drops for Aequus Pharmaceuticals
Historical stock prices
Current Share Price	CA$0.005
52 Week High	CA$0.029
52 Week Low	CA$0.0005
Beta	-0.013
11 Month Change	-37.50%
3 Month Change	-28.57%
1 Year Change	-66.67%
33 Year Change	-92.92%
5 Year Change	-93.93%
Change since IPO	-98.11%

Recent updates

Shareholder Returns

	AEQ	DE Pharmaceuticals	DE Market
7D	-28.6%	-1.2%	-0.02%
1Y	-66.7%	-20.1%	8.2%

Return vs Industry: AEQ underperformed the German Pharmaceuticals industry which returned -22% over the past year.

Return vs Market: AEQ underperformed the German Market which returned 7.4% over the past year.

Price Volatility

Is AEQ's price volatile compared to industry and market?
AEQ volatility
AEQ Average Weekly Movement	27.1%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: AEQ's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: AEQ's weekly volatility has decreased from 177% to 27% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2013	12	Doug Janzen	www.aequuspharma.ca

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on commercializing value-added products in specialty therapeutic areas in Canada. The company markets and distributes ZIMED PF, a preservative-free bimatoprost prescription drug for the treatment of glaucoma. It also develops REV-0100 for the treatment of stargardt disease that is in pre-clinical trial.

Aequus Pharmaceuticals Inc. Fundamentals Summary

How do Aequus Pharmaceuticals's earnings and revenue compare to its market cap?
AEQ fundamental statistics
Market cap	€455.62k
Earnings (TTM)	-€1.84m
Revenue (TTM)	€283.86k

1.6x

P/S Ratio

-0.2x

P/E Ratio

Is AEQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AEQ income statement (TTM)
Revenue	CA$413.17k
Cost of Revenue	CA$192.34k
Gross Profit	CA$220.83k
Other Expenses	CA$2.90m
Earnings	-CA$2.68m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.02
Gross Margin	53.45%
Net Profit Margin	-647.62%
Debt/Equity Ratio	-95.3%

How did AEQ perform over the long term?

See historical performance and comparison

AEQ Stock Overview

Risk Analysis

Aequus Pharmaceuticals Inc. Competitors

DB:VP2

€493.4k

XTRA:B8FK

€16.4m

DB:ECX

€1.2m

DUSE:SBX

€27.9m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Recent updates

Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)

Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)

Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)

Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in Canada

Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in Canada

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023

Aequus Announces Health Canada Notice of Compliance (NOC) for Zimed® Preservative Free (Bimatoprost 0.03%)

Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)

Aequus Pharmaceuticals Inc. Expects Health Canada Approval for Zimed® PF (Preservative Free)

Less than half of directors are independent

Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)

Less than half of directors are independent

Aequus Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

Aequus Pharmaceuticals Inc. Announces Resignation of Jason Flowerday from the Board of Directors

Aequus Pharmaceuticals Inc. Announces Canadian Filing of NDS for Preservative-Free Glaucoma Medication

High number of new directors

Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)

Aequus Pharmaceuticals Inc. Launches Evolve Eyedrops to Eye Care Professionals in Canada

Aequus Pharmaceuticals Inc. announced that it has received CAD 1 million in funding

Aequus Pharmaceuticals Inc. Appoints Marc Lustig as a Director

Aequus Pharmaceuticals Inc. announced that it expects to receive CAD 1 million in funding

Third quarter 2020 earnings released: CA$0.003 loss per share

Aequus Pharmaceuticals Inc. Announces Resignation of Anne Stevens as Chief Operating Officer

Aequus Pharmaceuticals Inc. Receives Approval for New ‘Evolve - Intensive Gel’ Lubricating Eye Drops in Canada

Aequus Pharmaceuticals Inc. Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada with Sandoz Canada Inc

Aequus Announces Expansion of Medicom Partnership and Filing with Health Canada for Additional Evolve Dry Eye Product

First half earnings released

Aequus Pharmaceuticals Inc. has completed a Composite Units Offering in the amount of CAD 2.5 million.

Aequus Pharmaceuticals Inc.(TSXV:AQS) dropped from S&P/TSX Venture Composite Index

Shareholder Returns

Price Volatility

About the Company

Aequus Pharmaceuticals Inc. Fundamentals Summary

1.6x

-0.2x

Earnings & Revenue